GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (XAMS:PHARM) » Definitions » Cyclically Adjusted PB Ratio

Pharming Group (XAMS:PHARM) Cyclically Adjusted PB Ratio : 5.20 (As of Jun. 04, 2025)


View and export this data going back to 1998. Start your Free Trial

What is Pharming Group Cyclically Adjusted PB Ratio?

As of today (2025-06-04), Pharming Group's current share price is €1.039. Pharming Group's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was €0.20. Pharming Group's Cyclically Adjusted PB Ratio for today is 5.20.

The historical rank and industry rank for Pharming Group's Cyclically Adjusted PB Ratio or its related term are showing as below:

XAMS:PHARM' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.13   Med: 7.74   Max: 21.2
Current: 5.1

During the past years, Pharming Group's highest Cyclically Adjusted PB Ratio was 21.20. The lowest was 2.13. And the median was 7.74.

XAMS:PHARM's Cyclically Adjusted PB Ratio is ranked worse than
80.06% of 672 companies
in the Biotechnology industry
Industry Median: 1.475 vs XAMS:PHARM: 5.10

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Pharming Group's adjusted book value per share data for the three months ended in Mar. 2025 was €0.289. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €0.20 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Pharming Group Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Pharming Group's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Cyclically Adjusted PB Ratio Chart

Pharming Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 20.00 9.13 8.41 6.41 4.81

Pharming Group Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.99 4.22 4.01 4.81 3.89

Competitive Comparison of Pharming Group's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Pharming Group's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharming Group's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Pharming Group's Cyclically Adjusted PB Ratio falls into.


;
;

Pharming Group Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Pharming Group's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.039/0.20
=5.20

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharming Group's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Pharming Group's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.289/133.3300*133.3300
=0.289

Current CPI (Mar. 2025) = 133.3300.

Pharming Group Quarterly Data

Book Value per Share CPI Adj_Book
201506 0.068 100.230 0.090
201509 0.062 100.500 0.082
201512 0.058 99.730 0.078
201603 0.052 100.310 0.069
201606 0.043 100.260 0.057
201609 0.036 100.570 0.048
201612 0.060 100.710 0.079
201703 0.063 101.440 0.083
201706 0.014 101.370 0.018
201709 0.013 102.030 0.017
201712 0.028 101.970 0.037
201803 0.055 102.470 0.072
201806 0.066 103.100 0.085
201809 0.079 103.950 0.101
201812 0.100 103.970 0.128
201903 0.110 105.370 0.139
201906 0.125 105.840 0.157
201909 0.144 106.700 0.180
201912 0.167 106.800 0.208
202003 0.183 106.850 0.228
202006 0.200 107.510 0.248
202009 0.213 107.880 0.263
202012 0.236 107.850 0.292
202103 0.242 108.870 0.296
202106 0.255 109.670 0.310
202109 0.255 110.790 0.307
202112 0.263 114.010 0.308
202203 0.272 119.460 0.304
202206 0.290 119.050 0.325
202209 0.310 126.890 0.326
202212 0.294 124.940 0.314
202303 0.284 124.720 0.304
202306 0.281 125.830 0.298
202309 0.298 127.160 0.312
202312 0.299 126.450 0.315
202403 0.281 128.580 0.291
202406 0.303 129.910 0.311
202409 0.300 131.610 0.304
202412 0.310 131.630 0.314
202503 0.289 133.330 0.289

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pharming Group  (XAMS:PHARM) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Pharming Group Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Pharming Group's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharming Group Business Description

Industry
Traded in Other Exchanges
Address
Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

Pharming Group Headlines

No Headlines